<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261415</url>
  </required_header>
  <id_info>
    <org_study_id>244-2014</org_study_id>
    <nct_id>NCT02261415</nct_id>
  </id_info>
  <brief_title>The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial</brief_title>
  <acronym>HeLiX</acronym>
  <official_title>The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial: Tranexamic Acid (TXA) Versus Placebo to Reduce Perioperative Blood Transfusion in Patients Undergoing Liver Resection: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HepatoPancreaticoBiliary (HPB) Concept Team</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III multicentre randomized controlled trial (RCT) to evaluate the impact of
      tranexamic acid (TXA) on perioperative blood transfusion in patients undergoing liver
      resection. The rationale for this study includes: (1) experimental evidence supporting the
      use of TXA in other surgical populations; (2) lack of evidence in patients undergoing liver
      resection; (3) clinical uncertainty and extensive support amongst hepatobiliary surgeons,
      anaesthesiologists, and hematologists for this proposed trial; (4) a feasible and efficient
      study design; and (5) the importance of the question: incidence of blood transfusion in
      patients undergoing liver resection is high, and the consequences serious. The sample size
      for this study is 1230 participants.Participants enrolled in the prior Vanguard study will
      proceed directly into the RCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose Compelling biological rationale and indirect evidence from other settings suggest
      that there is potential benefit to administering TXA to patients undergoing liver resection.
      A lack of consensus in the hepatobiliary community and lack of direct evidence in patients
      undergoing liver resection mandate a RCT.

      Hypothesis To determine the impact of perioperative administration of TXA to patients
      undergoing liver resection on the need for blood transfusion and long-term survival.

      Justification If TXA use in liver resection resulted in an important decrease in blood
      transfusions, clinical practice worldwide would be likely to change. Over 2000 patients in
      Canada undergo liver resection annually and could benefit from this simple, low-cost
      intervention. This intervention could easily be implemented in other countries, where many
      more patients undergo liver resection annually. Furthermore, TXA may be beneficial in other
      operative fields where bleeding is a major problem, including thoracic surgery, colorectal
      surgery, and many others.

      Objectives

      The primary outcome of the RCT will be:

      1) Receipt of blood transfusion (% transfused): 7 days

      The secondary outcomes of the RCT are:

        1. Intraoperative blood loss will be assessed by adding the net weight of sponges and fluid
           suction (minus irrigation and intraoperative bile or other fluids in suction/sponge)

        2. Total blood loss (postoperative day (POD)0 - POD7) will be assessed by Gross' formula,
           which uses the maximum postoperative decrease in the level of hemoglobin adjusted for
           the weight and height of the patient

        3. Number of packed red blood cells (PRBC) units transfused (POD0 - POD7)

        4. Postoperative incidence of symptomatic venous thromboembolic event confirmed with either
           computed tomography (CT) angiogram (for pulmonary embolism) or venous Doppler ultrasound
           (for deep venous thrombosis) (within 90 days of surgery)

        5. Postoperative complications (within 90 days of surgery) will be determined using the
           Clavien-Dindo classification

        6. Recurrence free survival (within 5 years of surgery) will be determined by review of
           patient medical record every 6 months until 5 years post-surgery

           a. Recurrence free survival is defined as the time from POD0 to the first event that is
           recurrent (local or distal) cancer or death (from any cause)

        7. Overall survival (within 5 years of surgery) will be determined by review of patient
           medical record every 6 months until 5 years post-surgery

           a. Overall survival is defined as the time from date of POD0 to death from any cause

        8. QOL will be determined by administering European Organization for Research and Treatment
           of Cancer (EORTC) Quality of Life Questionnaire (QLQ) -C30 and the QLQ- Liver Metastases
           Colorectal (LMC) 21 at baseline, 30 and 90 days following surgery

        9. Perioperative mortality will be recorded between POD0 and POD7

       10. Economic analysis will assess impact of TXA incorporation on health care resources and
           strategies for systematic utilization of TXA

      Research Method This is a Phase III multicentre randomized controlled trial (RCT) to evaluate
      the impact of tranexamic acid (TXA) on perioperative blood transfusion in patients undergoing
      liver resection. The trial will conceal allocation, maximize possible blinding, independently
      assess the appropriateness of transfusion, use strategies to limit loss to follow-up and
      crossovers, and use a conservative stopping rule. Patients will be administered a single dose
      of study drug intravenously immediately after induction of anaesthesia, followed by infusion
      over eight hours.

      Statistical Analysis Primary analysis will include only patients who underwent liver
      resection; patients who are randomized but do not receive liver resection (usually due to
      more advanced disease identified intraoperatively) will be excluded. A sensitivity analysis
      will be conducted whereby all randomized patients are included in the assessment of the
      primary outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Receipt of blood transfusion (% transfused): 7 days</measure>
    <time_frame>7 days</time_frame>
    <description>Receipt of one or more RBC transfusions between Day 0 and Day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>7 days</time_frame>
    <description>Intraoperative blood loss will be assessed by adding the net weight of sponges and fluid suction (minus irrigation and intraoperative bile or other fluids in suction/sponge)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total blood loss</measure>
    <time_frame>7 days</time_frame>
    <description>Total blood loss (postoperative day (POD)0 - POD7) will be assessed by Gross' formula, which uses the maximum postoperative decrease in the level of hemoglobin adjusted for the weight and height of the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of packed red blood cells (PRBC) units transfused</measure>
    <time_frame>7 days</time_frame>
    <description>Number of packed red blood cells (PRBC) units transfused (POD0 - POD7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative incidence of symptomatic venous thromboembolic event</measure>
    <time_frame>90 days</time_frame>
    <description>Postoperative incidence of symptomatic venous thromboembolic event confirmed with either computed tomography (CT) angiogram (for pulmonary embolism) or venous Doppler ultrasound (for deep venous thrombosis) (within 90 days of surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications assessed using Clavien-Dindo Grading System</measure>
    <time_frame>90 days</time_frame>
    <description>Postoperative complications (within 90 days of surgery) will be determined using the Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Free Survival (within 5 years of surgery)</measure>
    <time_frame>60 months</time_frame>
    <description>Disease recurrence is defined as the clinical presence of cancer that has either been confirmed by biopsy, has had treatment initiated, or is documented in the treating physician's notes. Five year disease recurrence from day of surgery will be evaluated approximately every 6 months until 5 years via medical record review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (within 5 years of surgery)</measure>
    <time_frame>60 months</time_frame>
    <description>Overall survival is defined as the time from date of surgery to death from any cause. It will be determined by review of patient medical record every 6 months until 5 years post-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Assessment using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30</measure>
    <time_frame>Baseline, 30 days, 90 days</time_frame>
    <description>QOL will be determined by administering the EORTC QLQ-C30 at baseline, 30 and 90 days following surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Assessment using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Liver Module (LM)C21 Questionnaire</measure>
    <time_frame>Baseline, 30 days, 90 days</time_frame>
    <description>QOL will be determined by administering QLQ-LMC21 at baseline, 30 and 90 days following surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative mortality</measure>
    <time_frame>7 days</time_frame>
    <description>Perioperative mortality will be recorded between POD0 and POD7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the cost of tranexamic acid (TXA) versus placebo on perioperative blood transfusion in patients undergoing liver resection</measure>
    <time_frame>90 days</time_frame>
    <description>Economic analysis will assess impact of TXA incorporation on health care resources and strategies for systematic utilization of TXA. The analysis will be using data collected in the randomized controlled trial from a societal perspective.The output of the economic analysis is the incremental cost of TXA compared to placebo (control group).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Cancer</condition>
  <condition>Tumour</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid (TXA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline (0.9% sodium chloride)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 g saline bolus injection + 1 g saline infusion from induction over 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid (TXA)</intervention_name>
    <description>1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours</description>
    <arm_group_label>Tranexamic acid (TXA)</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>1 g saline bolus injection + 1 g saline infusion from induction over 8 hours</description>
    <arm_group_label>Normal saline (0.9% sodium chloride)</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient scheduled for open or laparoscopic liver surgery

          -  Age â‰¥18 years

          -  Cancer related diagnosis or indication (e.g. pre-cancer, suspicion of cancer, definite
             cancer)

        Exclusion Criteria:

          -  Severe anemia (hemoglobin (Hgb) levels &lt;90 g/l)

          -  Documented arterial or venous thrombosis at screening or in past three months (not
             including therapeutic portal vein embolization)

          -  Anticoagulants (other than low-molecular-weight heparin (LMWH) or heparin in
             prophylactic doses to prevent deep vein thrombosis), direct thrombin inhibitors or
             thrombolytic therapy administered or completed within last week

          -  Known disseminated intravascular coagulation

          -  Severe renal insufficiency (creatinine clearance (CrCl) &lt;30 ml/min)

          -  History of seizure disorder

          -  Pregnant or lactating (a negative urine pregnancy test must be obtained for women of
             child bearing potential during the pretreatment evaluation)

          -  Acquired disturbance of colour vision

          -  Hypersensitivity to TXA or any of the ingredients

          -  Unable to receive blood products (i.e. difficulty with cross matching, refuses blood
             transfusion, or a past history of unexplained severe transfusion reaction)

          -  Previously enrolled in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Karanicolas, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danusha Nandamalavan</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>77038</phone_ext>
    <email>Danusha.Nandamalavan@unityhealth.to</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Roke, BSc (Hons)</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>85391</phone_ext>
    <email>rachel.roke@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elijah Dixon</last_name>
      <phone>403-521-3323</phone>
      <email>elijah.dixon@calgaryhealthregion.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ish Bains</last_name>
      <phone>403-944-3649</phone>
      <email>Ish.Bains@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Elijah Dixon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kelowna General Hospital</name>
      <address>
        <city>Kelowna</city>
        <state>British Colombia</state>
        <zip>V1Y 1T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tess Topor</last_name>
      <email>Tess.Topor@interiorhealth.ca</email>
    </contact>
    <investigator>
      <last_name>Gareth Eeson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2YR</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 8E7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leyo Ruo</last_name>
      <phone>905-521-2100</phone>
      <email>ruol@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Lo</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>43921</phone_ext>
      <email>loe3@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Leyo Ruo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Health Research Insititute</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sulaiman Nanji</last_name>
      <phone>613-549-6666</phone>
      <email>Sulaiman.Nanji@kingstonhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Angel Zhou</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>6685</phone_ext>
      <email>angel.zhou@kingstonhsc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sulaiman Nanji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Skaro</last_name>
      <phone>(519)663-2904</phone>
      <email>Anton.Skaro@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Karen Dunn</last_name>
      <phone>519-646-6000</phone>
      <phone_ext>64825</phone_ext>
      <email>Karen.Dunn@lhsc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Anton Skaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Karanicolas, MD PhD</last_name>
      <phone>416-480-4774</phone>
      <email>paul.karanicolas@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Roke, BSc (Hons)</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>85391</phone_ext>
      <email>rachel.roke@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Karanicolas, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorian Facey</last_name>
      <phone>416-340-4800</phone>
      <email>Dorian.Facey@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Carol-Anne Moulton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Tsang</last_name>
      <phone>(416) 530-6818</phone>
      <email>MTsang@stjoestoronto.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kanthi Kavikondala</last_name>
      <phone>(416) 530-6818</phone>
      <email>KKavikondala@stjoestoronto.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Melanie Tsang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prosanto Chaudhury</last_name>
      <phone>519-934-1934</phone>
      <phone_ext>31951</phone_ext>
      <email>prosanto.chaudhury@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Cristina Al-Ali</last_name>
      <phone>519-934-1934</phone>
      <phone_ext>36569</phone_ext>
      <email>Cristina.Al-Ali@MUHC.MCGILL.CA</email>
    </contact_backup>
    <investigator>
      <last_name>Prosanto Chaudhury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood transfusion</keyword>
  <keyword>blood loss</keyword>
  <keyword>feasibility</keyword>
  <keyword>outcome</keyword>
  <keyword>liver resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

